JPH07501340A - 哺乳類の神経の増殖を促進する薬物 - Google Patents
哺乳類の神経の増殖を促進する薬物Info
- Publication number
- JPH07501340A JPH07501340A JP5510115A JP51011593A JPH07501340A JP H07501340 A JPH07501340 A JP H07501340A JP 5510115 A JP5510115 A JP 5510115A JP 51011593 A JP51011593 A JP 51011593A JP H07501340 A JPH07501340 A JP H07501340A
- Authority
- JP
- Japan
- Prior art keywords
- pdgf
- igf
- nerve
- cells
- proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000005036 nerve Anatomy 0.000 title claims description 45
- 229940079593 drug Drugs 0.000 title claims description 9
- 239000003814 drug Substances 0.000 title claims description 9
- 230000012010 growth Effects 0.000 title claims description 8
- 241000124008 Mammalia Species 0.000 title description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 33
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 14
- 239000003102 growth factor Substances 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 1
- 101001076308 Xenopus laevis Insulin-like growth factor III Proteins 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 58
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 30
- 230000008929 regeneration Effects 0.000 description 27
- 238000011069 regeneration method Methods 0.000 description 27
- 210000003050 axon Anatomy 0.000 description 25
- 230000035755 proliferation Effects 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 19
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 description 16
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 239000000710 homodimer Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 10
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 10
- 210000003497 sciatic nerve Anatomy 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000004116 schwann cell Anatomy 0.000 description 9
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 102000007547 Laminin Human genes 0.000 description 7
- 108010085895 Laminin Proteins 0.000 description 7
- 102000015336 Nerve Growth Factor Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000833 heterodimer Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 229940053128 nerve growth factor Drugs 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000003376 axonal effect Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 238000001243 protein synthesis Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 210000002241 neurite Anatomy 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 241000132500 Dahlia <angiosperm> Species 0.000 description 3
- 235000012040 Dahlia pinnata Nutrition 0.000 description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 108091008816 c-sis Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- QUCFVNGGGFLOES-ACQYNFKHSA-N (4s)-5-[[(2s)-1-[[(2s)-1-[[(2r)-6-amino-1-[[(1s)-1-carboxy-2-phenylethyl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2s)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCS(=O)(=O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 QUCFVNGGGFLOES-ACQYNFKHSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241000483002 Euproctis similis Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 101150081880 FGF1 gene Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101150007144 Intu gene Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010038109 Org 2766 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010076289 Platelet-Derived Growth Factor Receptors Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044162 human IGF1 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- FTCYIGBVOHNHCD-UHFFFAOYSA-N isaxonine Chemical compound CC(C)NC1=NC=CC=N1 FTCYIGBVOHNHCD-UHFFFAOYSA-N 0.000 description 1
- 229950002643 isaxonine Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007511 neuronal proliferation Effects 0.000 description 1
- 230000003018 neuroregenerative effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000009719 regenerative response Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- WBPYTXDJUQJLPQ-LLMNDNAOSA-N tylosin Chemical compound O=CCC1CC(C)C(=O)\C=C\C(\C)=C\C(COC2C(C(OC)C(O)C(C)O2)OC)C(CC)OC(=O)CC(O)C(C)C1OC(C(C1N(C)C)O)OC(C)C1OC1CC(C)(O)C(O)C(C)O1 WBPYTXDJUQJLPQ-LLMNDNAOSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
- 1.哺乳類の神経の増殖促進のための薬物生産における、精製されたPDGFの 使用法。
- 2.前記薬物がPDGF以外の第二の神経増殖促進因子を使用して生産されるこ とを特徴とする請求項1に記載の使用法。
- 3.前記第二の因子が増殖因子であることを特徴とする請求項2に記載の使用法 。
- 4.前記増殖因子がIGFであることを特徴とする請求項3に記載の使用法。
- 5.前記IGFがIGF−I、IGF−II、またはIGF−IIIであること を特徴とする請求項4に記載の使用法。
- 6.前記IGFがIGF−Iであることを特徴とする請求項5に記載の使用法。
- 7.前記IGF−I及びPDGFが薬理学的に許容可能な担体中で混合されてい ることを特徴とする請求項6に記載の使用法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79731591A | 1991-11-25 | 1991-11-25 | |
US797.315 | 1991-11-25 | ||
PCT/US1992/009545 WO1993010806A1 (en) | 1991-11-25 | 1992-11-04 | Medicament for promoting growth of mammalian nerve |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005292267A Division JP2006070040A (ja) | 1991-11-25 | 2005-10-05 | 哺乳類の神経の増殖を促進する薬物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07501340A true JPH07501340A (ja) | 1995-02-09 |
JP3747416B2 JP3747416B2 (ja) | 2006-02-22 |
Family
ID=25170486
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51011593A Expired - Lifetime JP3747416B2 (ja) | 1991-11-25 | 1992-11-04 | 哺乳類の神経の増殖を促進する薬物 |
JP2005292267A Pending JP2006070040A (ja) | 1991-11-25 | 2005-10-05 | 哺乳類の神経の増殖を促進する薬物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005292267A Pending JP2006070040A (ja) | 1991-11-25 | 2005-10-05 | 哺乳類の神経の増殖を促進する薬物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US6506727B1 (ja) |
EP (1) | EP0615452A4 (ja) |
JP (2) | JP3747416B2 (ja) |
AU (1) | AU673659B2 (ja) |
CA (1) | CA2123685C (ja) |
CH (1) | CH684573A5 (ja) |
WO (1) | WO1993010806A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012102100A1 (ja) * | 2011-01-26 | 2012-08-02 | 雪印メグミルク株式会社 | 感覚改善剤 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM678294A0 (en) * | 1994-07-13 | 1994-08-04 | Gropep Pty Ltd | Use of insulin-like growth factor in combination with insulin |
US5728676A (en) * | 1994-09-08 | 1998-03-17 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
US5849585A (en) * | 1995-05-10 | 1998-12-15 | Genetech, Inc. | Isolating and culturing Schwann cells |
US6033660A (en) * | 1995-05-10 | 2000-03-07 | Genentech, Inc. | Method of treating a nervous system injury with cultured schwann cells |
US5714385A (en) * | 1995-05-10 | 1998-02-03 | Genentech, Inc. | Media for culturing schwann cells |
US5965531A (en) * | 1995-08-31 | 1999-10-12 | National Institutes Of Health | Method of reducing perivascular lesions using insulin-like growth factor I |
SE9601243D0 (sv) * | 1996-03-29 | 1996-03-29 | Hans Arne Hansson | Promotion of regeneration of organized tissues |
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
GB0011278D0 (en) * | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
ATE435852T1 (de) | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
EP1912660A1 (en) * | 2005-08-11 | 2008-04-23 | Medigenes Co., Ltd. | Pharmaceutical composition for the treatment of nerve damage comprising blood plasma or serum |
US7892573B2 (en) * | 2006-02-10 | 2011-02-22 | Wake Forest University Health Sciences | Nerve regeneration employing keratin biomaterials |
EP2594295A1 (en) | 2011-11-16 | 2013-05-22 | Servicio Andaluz De Salud | Nerve implants based on a compacted biomaterial containing cells |
US10597636B2 (en) | 2014-09-19 | 2020-03-24 | University Of Florida Research Foundation, Inc. | Electroactive polymeric scaffolds and method for delivering nerve growth factor to nerve tissue |
EP3206670A4 (en) | 2014-10-14 | 2018-06-20 | Samuel Lynch | Compositions for treating wounds |
EP3011981A1 (en) | 2014-10-24 | 2016-04-27 | Histocell, S.L. | A biomaterial scaffold for regenerating the oral mucosa |
CN113544195B (zh) * | 2019-03-14 | 2023-05-02 | 美国陶氏有机硅公司 | 具有聚(甲基)丙烯酸酯基团的聚有机硅氧烷及其制备方法和用途 |
WO2024173925A1 (en) * | 2023-02-17 | 2024-08-22 | Ohio State Innovation Foundation | Methods and compositions to treat axonal injury pathologies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0593065B1 (en) * | 1985-09-12 | 2002-08-21 | Scios Inc. | Recombinant fibroblast growth factors |
CA1322714C (en) | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
US5019559A (en) * | 1986-11-14 | 1991-05-28 | President And Fellows Of Harvard College | Wound healing using PDGF and IGF-II |
US4878913A (en) * | 1987-09-04 | 1989-11-07 | Pfizer Hospital Products Group, Inc. | Devices for neural signal transmission |
SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
US4775073A (en) | 1987-10-01 | 1988-10-04 | Total Containment | Multi-purpose fitting system |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5656605A (en) * | 1994-01-26 | 1997-08-12 | Institute Of Molecular Biology, Inc. | Device to promote drug-induced nerve regeneration |
-
1992
- 1992-11-04 CA CA002123685A patent/CA2123685C/en not_active Expired - Lifetime
- 1992-11-04 CH CH2309/93A patent/CH684573A5/de not_active IP Right Cessation
- 1992-11-04 JP JP51011593A patent/JP3747416B2/ja not_active Expired - Lifetime
- 1992-11-04 AU AU30668/92A patent/AU673659B2/en not_active Expired
- 1992-11-04 WO PCT/US1992/009545 patent/WO1993010806A1/en not_active Application Discontinuation
- 1992-11-04 EP EP92924312A patent/EP0615452A4/en not_active Withdrawn
-
1994
- 1994-02-18 US US08/198,542 patent/US6506727B1/en not_active Expired - Lifetime
-
2005
- 2005-10-05 JP JP2005292267A patent/JP2006070040A/ja active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012102100A1 (ja) * | 2011-01-26 | 2012-08-02 | 雪印メグミルク株式会社 | 感覚改善剤 |
JPWO2012102100A1 (ja) * | 2011-01-26 | 2014-06-30 | 雪印メグミルク株式会社 | 感覚改善剤 |
JP5993308B2 (ja) * | 2011-01-26 | 2016-09-14 | 雪印メグミルク株式会社 | 感覚改善剤 |
US9884095B2 (en) | 2011-01-26 | 2018-02-06 | Megmilk Snow Brand Co., Ltd. | Milk-derived basic protein fraction as skin sensitivity improving agent |
Also Published As
Publication number | Publication date |
---|---|
CA2123685A1 (en) | 1993-06-10 |
AU3066892A (en) | 1993-06-28 |
WO1993010806A1 (en) | 1993-06-10 |
JP3747416B2 (ja) | 2006-02-22 |
CA2123685C (en) | 2003-10-07 |
CH684573A5 (de) | 1994-10-31 |
AU673659B2 (en) | 1996-11-21 |
EP0615452A4 (en) | 1995-07-12 |
EP0615452A1 (en) | 1994-09-21 |
JP2006070040A (ja) | 2006-03-16 |
US6506727B1 (en) | 2003-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07501340A (ja) | 哺乳類の神経の増殖を促進する薬物 | |
AU2007229301B2 (en) | Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents | |
Frautschy et al. | Localization of basic fibroblast growth factor and its mRNA after CNS injury | |
Baird et al. | Fibroblast growth factors | |
Lanfranconi et al. | Growth factors in ischemic stroke | |
US8158578B2 (en) | Methods for treating neurological deficits | |
Cuevas et al. | Vascular response to basic fibroblast growth factor when infused onto the normal adventitia or into the injured media of the rat carotid artery. | |
KR19980703748A (ko) | 청력손실 치료용 제약학적 조성물 | |
EP1699915A1 (de) | Verfahren zur regeneration von gewebe | |
AU2005291810A1 (en) | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds | |
Roque et al. | Cultured Müller cells have high levels of epidermal growth factor receptors. | |
EP3790574A1 (en) | Targeting anabolic drugs for accelerated fracture repair | |
EP0535148A4 (ja) | ||
AU715255B2 (en) | Pharmaceutical composition containing an activin or inhibin stimulator | |
Choi et al. | Autologous fibrin glue in peripheral nerve regeneration in vivo | |
Chen et al. | Effects of basic fibroblast growth factor (bFGF)-neutralizing antibody and platelet factor 4 on facial nerve regeneration | |
JPH101439A (ja) | 神経変性疾患治療剤 | |
US20010007657A1 (en) | Compositions and methods for manipulating glial progenitor cells and treating neurological deficits | |
JPH07316066A (ja) | 創傷治癒剤 | |
JP2009506982A (ja) | 神経保護効果のある化合物 | |
Klintworth et al. | Nature of Angiogenic Factor | |
Ma et al. | Role of platelets in gastric ulcer healing: a delivery system for growth factors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041012 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051005 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051118 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091209 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101209 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101209 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111209 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111209 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121209 Year of fee payment: 7 |
|
EXPY | Cancellation because of completion of term |